Alimera Sciences, Inc. (ALIM) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alimera Sciences, Inc. (NASDAQ:ALIM) in a report published on Friday, October 27th. The firm currently has a $5.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on ALIM. Zacks Investment Research upgraded Alimera Sciences from a hold rating to a buy rating and set a $1.50 price objective on the stock in a research note on Monday, July 10th. Cowen and Company reiterated a buy rating and issued a $3.00 price objective on shares of Alimera Sciences in a research note on Tuesday, July 11th. Finally, ValuEngine upgraded Alimera Sciences from a sell rating to a hold rating in a research note on Thursday, July 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Alimera Sciences currently has a consensus rating of Hold and an average price target of $3.38.

Alimera Sciences (NASDAQ:ALIM) opened at $1.25 on Friday. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65. Alimera Sciences has a 52 week low of $1.04 and a 52 week high of $1.72.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://ledgergazette.com/2017/11/13/alimera-sciences-inc-alim-receives-buy-rating-from-hc-wainwright.html.

A number of large investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its holdings in Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 35,200 shares during the last quarter. JW Asset Management LLC increased its holdings in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares during the last quarter. KCG Holdings Inc. increased its holdings in Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the last quarter. Finally, Kennedy Capital Management Inc. purchased a new position in Alimera Sciences in the first quarter valued at $467,000. 36.82% of the stock is currently owned by hedge funds and other institutional investors.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply